Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations
Condition(s):Metastatic Pancreatic CancerLast Updated:December 28, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Pancreatic CancerLast Updated:December 28, 2023Recruiting
Condition(s):Metastatic Pancreatic CancerLast Updated:May 31, 2019Withdrawn
Condition(s):Metastatic Pancreatic CancerLast Updated:July 18, 2023Terminated
Condition(s):Metastatic Pancreatic CancerLast Updated:August 28, 2019Terminated
Condition(s):Metastatic Pancreatic CancerLast Updated:February 23, 2024Completed
Condition(s):Metastatic Pancreatic CancerLast Updated:November 22, 2019Completed
Condition(s):Metastatic Pancreatic CancerLast Updated:February 12, 2024Recruiting
Condition(s):Metastatic Pancreatic CancerLast Updated:March 5, 2024Recruiting
Condition(s):Metastatic Pancreatic CancerLast Updated:March 8, 2023Completed
Condition(s):Pancreatic Neoplasm; Metastatic Pancreatic Cancer; Locally Advanced Pancreatic AdenocarcinomaLast Updated:August 16, 2021Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.